After determining the mode of action of the selected compound upon binding to gp96, we evaluated its in vivo effect on various phenotypes that are associated with SLE symptoms using the transgenic mice displaying SLE-like phenotypes resulting from the chronic surface presentation of gp96. This evidence concerns the gene HSP90B1 and systemic lupus erythematosus.